Novo Nordisk Shares Tumble as CEO Warns of 'Painful' Price Pressures in Weight-Loss Drug Market
The maker of blockbuster drugs Wegovy and Ozempic sees its stock plunge 18% after slashing profit forecasts, citing unprecedented competition, patent expiries, and a landmark U.S. pricing deal.